Stock Analysis on Net
Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Analysis of Liquidity Ratios

Microsoft Excel

Liquidity Ratios (Summary)

Celgene Corp., liquidity ratios

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Current ratio 2.23 4.99 3.67 4.77 4.60
Quick ratio 2.00 4.67 3.24 4.05 4.13
Cash ratio 1.49 4.03 2.69 3.33 3.57

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).


An analysis of liquidity ratios between 2014 and 2018 reveals a period of high short-term solvency followed by a substantial decline in the final year of the observed period.

Current Ratio
The current ratio exhibited volatility, rising from 4.60 in 2014 to a peak of 4.99 in 2017, before decreasing sharply to 2.23 by December 31, 2018. Although the 2018 level represents a significant reduction, it remains well above the standard threshold of 1.0, indicating a sustained ability to meet short-term obligations.
Quick Ratio
The quick ratio followed a trajectory closely mirroring the current ratio, moving from 4.13 in 2014 to 4.67 in 2017, and ending at 2.00 in 2018. The narrow variance between the current and quick ratios suggests that inventories represent a minimal portion of the total current assets.
Cash Ratio
The cash ratio demonstrated a similar pattern, peaking at 4.03 in 2017 and falling to 1.49 in 2018. The high values maintained through 2017 indicate a heavy concentration of cash and cash equivalents relative to current liabilities, while the 2018 decline reflects a meaningful shift in the immediate liquidity position.

Overall, the consistent alignment across all three liquidity metrics suggests that short-term financial health was driven primarily by cash holdings. The precipitous drop across all ratios in 2018 indicates a significant change in capital allocation or a substantial increase in current liabilities during that fiscal year.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Current Ratio

Celgene Corp., current ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Current assets 9,067 14,892 10,868 9,401 9,713
Current liabilities 4,057 2,987 2,959 1,969 2,112
Liquidity Ratio
Current ratio1 2.23 4.99 3.67 4.77 4.60
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Current ratio = Current assets ÷ Current liabilities
= 9,067 ÷ 4,057 = 2.23

2 Click competitor name to see calculations.


Between 2014 and 2018, the liquidity position exhibited significant volatility, characterized by an initially strong buffer followed by a sharp contraction in the final year of the period.

Current Assets Analysis
Current assets remained relatively stable between 2014 and 2016, followed by a substantial increase to 14,892 million US$ in 2017. However, a significant reduction occurred in 2018, with assets falling to 9,067 million US$, representing the lowest level recorded during the five-year period.
Current Liabilities Analysis
Current liabilities demonstrated a general upward trajectory. Following a slight decrease in 2015, obligations rose steadily, culminating in a sharp increase to 4,057 million US$ by December 31, 2018, which is nearly double the amount reported in 2014.
Current Ratio Interpretation
The current ratio fluctuated at high levels between 4.60 and 4.99 from 2014 to 2017, indicating an exceptionally strong capacity to cover short-term debts. In 2018, the ratio experienced a steep decline to 2.23. This contraction was the result of a simultaneous decrease in current assets and an increase in current liabilities, marking a shift toward a less conservative liquidity posture compared to previous years.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Quick Ratio

Celgene Corp., quick ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Cash and cash equivalents 4,234 7,013 6,170 4,880 4,122
Debt securities available-for-sale 496 3,219 — — —
Equity investments with readily determinable fair values 1,312 1,810 — — —
Marketable securities available-for-sale — — 1,800 1,672 3,425
Accounts receivable, net of allowances 2,066 1,921 1,621 1,421 1,167
Total quick assets 8,108 13,963 9,590 7,973 8,713
 
Current liabilities 4,057 2,987 2,959 1,969 2,112
Liquidity Ratio
Quick ratio1 2.00 4.67 3.24 4.05 4.13
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 8,108 ÷ 4,057 = 2.00

2 Click competitor name to see calculations.


The liquidity profile from 2014 to 2018 is characterized by significant volatility in quick assets and a steady increase in current liabilities toward the end of the period. While the quick ratio remained well above the standard benchmark of 1.0, a notable contraction in liquidity occurred in the final year of the period analyzed.

Total Quick Assets Trend
Quick assets exhibited an inconsistent trajectory, declining slightly in 2015 before rising to a peak of 13,963 million US$ in 2017. This peak was followed by a sharp contraction in 2018, with assets falling to 8,108 million US$, the lowest level recorded since 2015.
Current Liabilities Analysis
Current liabilities remained relatively stable between 2014 and 2015 but began a general upward trend starting in 2016. A substantial increase was observed in 2018, where liabilities reached 4,057 million US$, representing a significant increase over the prior year.
Quick Ratio Interpretation
The quick ratio fluctuated from 4.13 in 2014 to a high of 4.67 in 2017. The most significant shift occurred between 2017 and 2018, where the ratio dropped to 2.00. This decline was driven by the simultaneous decrease in quick assets and the increase in current liabilities, indicating a reduced, though still sufficient, margin of safety for meeting short-term obligations without relying on inventory sales.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Cash Ratio

Celgene Corp., cash ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Cash and cash equivalents 4,234 7,013 6,170 4,880 4,122
Debt securities available-for-sale 496 3,219 — — —
Equity investments with readily determinable fair values 1,312 1,810 — — —
Marketable securities available-for-sale — — 1,800 1,672 3,425
Total cash assets 6,042 12,042 7,970 6,552 7,547
 
Current liabilities 4,057 2,987 2,959 1,969 2,112
Liquidity Ratio
Cash ratio1 1.49 4.03 2.69 3.33 3.57
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 6,042 ÷ 4,057 = 1.49

2 Click competitor name to see calculations.


The liquidity position from 2014 to 2018 is characterized by a period of high cash sufficiency followed by a significant contraction in the final year. While the ability to cover short-term obligations remained intact, there was a notable shift in the relationship between liquid assets and current liabilities.

Cash Asset Trends
Total cash assets exhibited significant volatility over the five-year period. After a slight decline in 2015 and a recovery in 2016, cash assets peaked in 2017 at 12,042 million US$. This was followed by a sharp reduction to 6,042 million US$ in 2018, representing a decrease of approximately 50% in total cash holdings within one year.
Current Liability Growth
A steady upward trend in current liabilities is observed from 2015 onwards. Short-term obligations increased from 1,969 million US$ in 2015 to 4,057 million US$ in 2018. This growth reflects a consistent increase in the company's short-term financial commitments over the analyzed timeframe.
Cash Ratio Dynamics
The cash ratio remained robust between 2014 and 2017, reaching its maximum value of 4.03 in 2017. However, 2018 saw a precipitous drop to 1.49. This decline was driven by the dual impact of diminishing cash reserves and expanding current liabilities.

Despite the sharp decline observed in the final year, the cash ratio remained above 1.0 throughout the entire period. This indicates that the entity maintained a sufficient cash balance to extinguish all current liabilities without necessitating the liquidation of other current assets or the acquisition of additional financing.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?